Departments of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Clin Cancer Res. 2010 Feb 15;16(4):1226-35. doi: 10.1158/1078-0432.CCR-09-2350. Epub 2010 Feb 9.
The goal of this study was to examine the effect of tobacco use on disease recurrence (local/regional recurrence, distant metastasis, or second primary) among patients with human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx (SCCOP) following a complete response to chemoradiation therapy.
Between 1999 and 2007, 124 patients with advanced SCCOP (86% with stage IV) and adequate tumor tissue for HPV analysis who were enrolled in one of two consecutive University of Michigan treatment protocols were prospectively included in this study. Patients were categorized as never-, former, or current tobacco users. The primary end points were risk of disease recurrence and time to recurrence; secondary end points were disease-specific survival and overall survival.
One hundred and two patients (82.3%) had HPV-positive tumors. Over two thirds (68%) of patients with HPV-positive tumors were tobacco users. Among HPV-positive patients, current tobacco users were at significantly higher risk of disease recurrence than never-tobacco users (hazard ratio, 5.2; confidence interval, 1.1-24.4; P = 0.038). Thirty-five percent of HPV-positive ever tobacco users recurred compared with only 6% of HPV-positive never users and 50% of HPV-negative patients. All HPV-negative patients were tobacco users and had significantly shorter times to recurrence (P = 0.002), and had reduced disease-specific survival (P = 0.004) and overall survival (P < 0.001) compared with HPV-positive patients. Compared with HPV-positive never-tobacco users, those with a tobacco history showed a trend for reduced disease-specific survival (P = 0.064) but not overall survival (P = 0.221).
Current tobacco users with advanced, HPV-positive SCCOP are at higher risk of disease recurrence compared with never-tobacco users.
本研究旨在探讨 HPV 阳性口咽鳞癌(SCCOP)患者在接受放化疗完全缓解后,吸烟对疾病复发(局部/区域复发、远处转移或第二原发癌)的影响。
1999 年至 2007 年间,共有 124 例晚期 SCCOP 患者(86%为 IV 期)入组本研究,这些患者在入组时均接受了连续两个密歇根大学治疗方案之一的治疗,且有足够的肿瘤组织进行 HPV 分析。患者被分为从不吸烟、曾经吸烟和当前吸烟三类。主要终点为疾病复发风险和复发时间;次要终点为疾病特异性生存率和总生存率。
102 例患者(82.3%)的肿瘤呈 HPV 阳性。在 HPV 阳性肿瘤患者中,超过三分之二(68%)为吸烟者。与从不吸烟的患者相比,当前吸烟的 HPV 阳性患者疾病复发的风险显著更高(风险比,5.2;95%置信区间,1.1-24.4;P=0.038)。35%的 HPV 阳性曾吸烟患者复发,而 HPV 阳性从不吸烟患者仅为 6%,HPV 阴性患者为 50%。所有 HPV 阴性患者均为吸烟者,且复发时间明显更短(P=0.002),疾病特异性生存率(P=0.004)和总生存率(P<0.001)也显著降低,与 HPV 阳性患者相比。与 HPV 阳性从不吸烟的患者相比,有吸烟史的患者疾病特异性生存率呈下降趋势(P=0.064),但总生存率无明显差异(P=0.221)。
与从不吸烟的患者相比,晚期 HPV 阳性 SCCOP 患者中当前吸烟患者疾病复发的风险更高。